Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21202186 | 1.00 | ROCK1 (0.41) | ROCK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL22281389 | 0.85 | ROCK2 (0.44) | ROCK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21217821 | 0.83 | ROCK1 (0.60) | ROCK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL24094169 | 0.83 | NPC1 (0.55) | ROCK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21198538 | 0.83 | ROCK2 (0.56) | ROCK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21217626 | 0.82 | ROCK2 (0.37) | ROCK1ROCK2 | |
| SCHEMBL21217815 | 0.82 | ROCK2 (0.53) | ROCK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21198160 | 0.81 | MEN1 (0.41) | ROCK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL29672455 | 0.81 | MEN1 (0.41) | ROCK1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL22966729 | 0.80 | TNIK (0.44) | ROCK1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11878020-B2 | Modulators of Rho-associated protein kinase | REDX PHARMA PLC (GB) | 2024-01-23 | — | — | US | disclosed |
| CN-111655681-B | Heterocyclylamino-substituted triazoles as modulators of Rho-related protein kinases | 莱德克斯制药公共有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878020-B2 | Modulators of Rho-associated protein kinase | ROCK2, ROCK1, RHOA | ROCK1 2/4885MEN1 2942/4885KMT2A 2289/4885 |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | ROCK1 2/4885MEN1 2942/4885KMT2A 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.